NS5A inhibitors: A new breakthrough for the treatment of chronic hepatitis C  by Asselah, Tarik
International HepatologyNS5A inhibitors: A new breakthrough for the treatment of
chronic hepatitis C
Tarik Asselah⇑
Hôpital Beaujon, APHP, Clichy, France and Univeristy Denis Diderot Paris 7 and INSERM U773, CRB3, FranceCOMMENTARY ON: lication that offers potential as part of a therapeutic regimen based
Chemical genetics strategy identiﬁes an HCV NS5A inhibitor
with a potent clinical effect. Gao M, Nettles RE, Belema M,
Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley
DR, Sun JH, O’Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien
C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. Nature.
2010;465(7294):96–100. Copyright (2010). Abstract reprinted
with permission from Macmillan Publishers Ltd.
http://www.ncbi.nlm.nih.gov/pubmed/20410884
Abstract: The worldwide prevalence of chronic hepatitis C virus
(HCV) infection is estimated to be approaching 200 million people.
Current therapy relies upon a combination of pegylated interferon-
alpha and ribavirin, a poorly tolerated regimen typically associated
with less than 50% sustained virological response rate in those
infected with genotype 1 virus. The development of direct-acting
antiviral agents to treat HCV has focused predominantly on inhibi-
tors of the viral enzymes NS3 protease and the RNA-dependent
RNA polymerase NS5B. Here we describe the proﬁle of BMS-
790052, a small molecule inhibitor of the HCV NS5A protein that
exhibits picomolar half-maximum effective concentrations (EC(50))
towards replicons expressing a broad range of HCV genotypes and
the JFH-1 genotype 2a infectious virus in cell culture. In a phase I
clinical trial in patients chronically infected with HCV, administra-
tion of a single 100-mg dose of BMS-790052 was associated with a
3.3 log(10) reduction in mean viral load measured 24 h post-dose
that was sustained for an additional 120 h in two patients infected
with genotype 1b virus. Genotypic analysis of samples taken at base-
line, 24 and 144 h post-dose revealed that the major HCV variants
observed had substitutions at amino-acid positions identiﬁed using
the in vitro replicon system. These results provide the ﬁrst clinical
validation of an inhibitor of HCV NS5A, a protein with no known
enzymatic function, as an approach to the suppression of virus rep-Journal of Hepatology 20
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Recently, Gao et al. identiﬁed a potent HCV inhibitor targeting the
non-traditional viral protein NS5A [1]. HCV is an enveloped virus
with a 9.6 kb single-stranded RNA genome [2], a member of the
Flaviviridae family, genus Hepacivirus. The HCV lifecycle begins
with virion entry into the cytosol with a complex series of steps
including attachment to its speciﬁc host cell receptor. The HCV
RNA genome serves as a template for viral replication via a neg-
ative strand copy and as a messenger RNA for virus production. It
is translated into a polyprotein that is cleaved by both host and
viral proteases to release the individual enzymes and proteins
that mediate virus replication, assembly, and release. All of the
HCV enzymes are essential for HCV replication and are, therefore,
potential targets for drug discovery. The knowledge of the struc-
tures of the NS3 protease and NS5B polymerase has allowed
structure-based drug design, leading to the development of
inhibitors of these enzymes. Several ﬁndings suggest that HCV
modulation of IFN induction and signalling attenuates the
expression of IFN-stimulated genes, allowing HCV to escape the
antiviral actions of the host response [3].
The standard of care (SOC) is the association of pegylated
interferon (PEG-IFN) plus ribavirin (RBV). Sustained virological
response (SVR) deﬁned by an absence of HCV RNA measured at
24 weeks after cessation of treatment and equivalent to viral
eradication, is associated with a reduction in the risk of cirrhosis
and HCC [4]. It has been recently reported that 12 weeks post-
treatment follow-up is as relevant as 24 weeks to deﬁne SVR
[5]. At present, in genotype 2 or 3 infected patients, SVR rates
approach 80%; in genotype 1 SVR rates reach less than 50%. It
has been shown that some interferon-stimulated genes are highly
expressed in non-responders; thus, pre-activation of the IFN sys-
tem in these patients appears to limit the effect of IFN antiviral
therapy [6].
New drug therapies such as protease and polymerase inhibi-
tors, designated as direct-acting antivirals (DAAs), are under
development [7]. In HCV genotype 1 patients, very promising
results have been reported when the protease inhibitors telapre-
vir or boceprevir are added to the current SOC. The ﬁnal results of
phase III studies have shown that they increase the SVR rates11 vol. 54 j 1069–1072
Fig. 1. The N terminus of NS5A (domain I) crystallized in alternative dimeric
forms. (A) Structure of NS5A. (B) Structure of BMS-790052.
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from less than 50% (PEG-IFN plus RBV) to approximately 70%
(PEG-IFN plus RBV plus protease inhibitor) [8–13]. The near
future SOC will consist of a regimen that combines a protease
inhibitor with PEG-IFN plus RBV.
A particularly interesting perspective would be IFN-sparing
regimens that rely solely on DAA combinations. Therefore, the
identiﬁcation and development of new molecules with different
mechanisms of action, having additive or synergistic effects, is
needed. The goals for a DAA combination should be to increase
antiviral efﬁcacy, minimize the emergence of resistance, and
limit side effects. The ﬁrst study of a combination of DAAs in
patients was the proof-of-concept INFORM-1 study [14]. In this
randomised, placebo-controlled, double-blind trial, 87 genotype
1 infected patients were randomized to receive up to 13 days of
either oral combination therapy with RG7227/danoprevir, a
NS3/4A protease inhibitor, and RG7128, a nucleoside polymerase
inhibitor, or with matched placebos. The median reduction in
HCV-RNA from the baseline was 5 log10, which fell below the
level of detection in 88% of the patients who received the highest
dose of both danoprevir (900 mg bid) and RG7128 (1000 mg bid).
No evidence of resistance to either compound was observed dur-
ing the study and no serious adverse events were reported. The
antiviral efﬁcacy was similar in naïve and treatment-experienced
patients, including non-responders. In the ﬁnal cohort of patients
who received the highest dose of RG7227 and RG7128, 100%
achieved early virological response after 24 weeks of PEG-IFN
and RBV treatment. The ﬁnal SVR results will certainly be
interesting.
There is a great need for additional HCV antivirals to provide
more effective, better-tolerated treatment options that can beBM
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ing successful treatment regimens. In general, the development
of antivirals has focused on targeting viral proteins with known
enzymatic activities, such as protease or polymerase that are
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Table 1. Resistance proﬁle of genotype 1a and 1b replicons exposed to BMS-
790052 adapted from [18].
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JOURNAL OF HEPATOLOGYhas recently been achieved that advances HCV inhibition beyond
these traditional approaches. Researchers at Bristol-Myers Squibb
have now reported that a compound, BMS-790052, with a new
mechanism of action led to dramatic reductions in viral load
and produced few side effects in a phase I clinical study [1].
BMS-790052 targets NS5A, a HCV non-structural protein that
possesses no enzymatic activity but plays a critical role in regu-
lating viral replication and host cell interactions. Structures of
NS5A and BMS-790052 are provided in Figs. 1A and 1B. Although
the function of HCV NS5A is still poorly understood, the BMS
researchers have shown that small molecules targeting this pro-
tein are potent and speciﬁc inhibitors of viral replication.
NS5A is a membrane-associated phosphoprotein present in
basally phosphorylated (p56) and hyperphosphorylated (p58)
forms [15,16]. It was previously reported that only p58-defective
mutants could be complemented in trans, and NS5A is involved in
HCV virion production, suggesting that different forms of NS5A
exert multiple functions at various stages of the viral life cycle.Table 2. Some combinations under development in phase 2 clinical studies.
Molecules  
GS9256 (NS3/4A inhibitor) and GS9190 (non-nuc polymerase inhibito
BI201335 (NS3/4A inhibitor) and BI297127 (non-nuc polymerase inhi
BMS-650032 (NS3/4A inhibitor) and BMS-790052 (NS5a inhibitor) 
Telaprevir (NS3/4A inhibitor) with VX-222 (non-nuc polymerase inhibi
RG7227 (NS3/4A inhibitor)/Ritonovir and RG7128 (Nuc polymerase i
IDX320 (NS3/4A inhibitor) and IDX184 (Nuc polymerase inhibitor) 
ABT-450 (NS3/4A inhibitor)/Ritonovir and ABT-072 (non-nuc polymer
Journal of Hepatology 2011The N terminus of NS5A (domain I) has been crystallized in alter-
native dimeric forms and contains both zinc- and RNA-binding
domains, properties that have been demonstrated in vitro [16]
(Fig. 1). NS5A has been shown to interact with a number of host
proteins and is implicated in interferon resistance in vivo [15].
The strategy used by Gao et al. to identify a lead HCV NS5A inhib-
itor provides a contemporary demonstration of the effectiveness
of an approach to drug discovery based on chemical genetics [17].
Indeed, this methodology is uniquely applicable to targets similar
to HCV NS5A for which precise functions are unknown and for
which the development of biochemical assays are infeasible.
The lead molecule was optimized into the clinical candidate
BMS-790052 whose chemical structure is shown in Fig. 1B. This
compound is active at picomolar concentrations in vitro towards
replicons expressing a broad range of HCV genotypes and acts in
an additive to synergistic fashion with interferon and other small
molecule antiviral compounds. Mean plasma concentration–time
proﬁle of BMS-790052 after single oral administration to healthy
subjects is shown in Fig. 2A. The effect of this compound on viral
load in HCV-infected subjects following single oral doses of the
compound are provided in Fig. 2B.
The resistance proﬁle of BMS-790052 is shown in Table 1
which reveals that, inhibitor sensitivity maps to the N terminus
of domain 1 of NS5A [1,18,19]. In addition, the BMS researchers
demonstrated that NS5A inhibitors, as well as an active-site
inhibitor that speciﬁcally binds NS3 protease, could block the
hyperphosphorylation of NS5A, which is believed to play an
essential role in the viral life cycle.
Phase II clinical studies combining BMS-790052 with the NS3
protease inhibitor BMS-650032 are ongoing and interim results
have shown that this combination therapy alone or with PEG-
IFN and RBV results in undetectable HCV RNA through 12 weeks
of therapy in HCV genotype 1 null responders [20].
At present, several studies of DAA combinations are ongoing
(Table 2) [20–22].
In conclusion, clinical proof-of-concept has recently been
achievedwithNS5A inhibitors, indicating that smallmolecules tar-
geting a non-traditional viral protein without any known enzy-
matic activity can also have profound antiviral effects in HCV-
infected subjects. Achieving high potency and selectivity against
anon-mammalian target, the traditional goal of antiviralmedicinal
chemistry, has in the past translated into awider therapeutic index
in the clinic. Although preliminary, these data indicate that inhib-
itors of HCV NS5A offer considerable promise for the treatment of
HCV infection. Once new DAAs become available, treatment strat-Company 
r) Gilead [21]
bitor) Boehringer [22]
BMS [20]
tor) xetreV
nhibitor) ehcoR
xinedI
ase inhibitor) ttobbA
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egies that combine several drugs with different mechanisms of
action could hopefully result in IFN- and/or RBV-sparing regimens.
Ongoing studies are directed towards demonstrating that such
combinations ofDAAshave synergistic antiviral potency, a low risk
of resistance with a good safety proﬁle.Conﬂict of interest
The authors who have taken part in this study have declared a
relationship with the manufacturers of the drugs involved. Tarik
Asselah has been an investigator or speaker for BMS, Gilead,
Merck, Roche, and Tibotec.
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